Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11444542 | 0.84 | LMNA (0.38) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL970779 | 0.78 | BRD4 (0.38) | LMNAMAPK1CYP2D6KMT2ATSHR | |
| SCHEMBL6651688 | 0.78 | IDO1 (0.40) | LMNAMAPK1SRCCYP2D6TSHR | |
| SCHEMBL1094149 | 0.78 | LMNA (0.46) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL5722203 | 0.76 | SRC (0.50) | LMNAMAPK1SRCCYP2D6POLB | |
| SCHEMBL970766 | 0.73 | HCAR2 (0.43) | LMNACYP2D6KMT2AALDH1A1KDM4E | |
| SCHEMBL7719881 | 0.73 | DPP4 (0.44) | LMNAKDM4E | |
| SCHEMBL971340 | 0.72 | ACP3 (0.41) | LMNAMAPK1CYP2D6CES2CES1 | |
| SCHEMBL5879080 | 0.72 | LMNA (0.46) | LMNAMAPK1SRCCYP2D6TSHR | |
| SCHEMBL13551473 | 0.71 | CYP2D6 (0.54) | LMNAMAPK1SRCCYP2D6CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810135-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. (US) | 2021-04-28 | — | — | EP | claimed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | Poviva Corp. | 2021-02-18 | — | — | US | claimed |
| EP-3765088-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | Poviva Corp. (US) | 2021-01-20 | — | — | EP | claimed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | claimed |
| WO-2019178360-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | POVIVA TEA, LLC (US) | 2019-09-19 | — | — | WO | claimed |
| EP-2448433-A2 | OMEGA-3 FATTY ACID ENRICHED BEVERAGES | Solae, LLC (US) | 2012-05-09 | — | — | EP | claimed |
| EP-2448431-A2 | OMEGA-3 FATTY ACID ENRICHED BAKED FOODS AND BAR COMPOSITIONS | Solae, LLC (US) | 2012-05-09 | — | — | EP | claimed |
| US-20120107478-A1 | Omega-3 Fatty Acid Enriched Baked Foods and Bar Composition | SOLAE, LLC (US) | 2012-05-03 | — | — | US | claimed |
| US-20120100257-A1 | Omega-3 Fatty Acid Enriched Beverages | SOLAE, LLC (US) | 2012-04-26 | — | — | US | claimed |
| WO-2011002802-A2 | OMEGA-3 FATTY ACID ENRICHED BAKED FOODS AND BAR COMPOSITIONS | SOLAE, LLC (US) | 2011-01-06 | — | — | WO | claimed |
| WO-2011002805-A2 | OMEGA-3 FATTY ACID ENRICHED BEVERAGES | SOLAE, LLC (US) | 2011-01-06 | — | — | WO | claimed |
| US-20260144834-A1 | ANTIMICROBIAL FEED ADDITIVE | Axitan Ltd. (GB) | 2026-05-28 | — | — | US | disclosed |
| US-12629319-B2 | Injection apparatus and method of use | MOBIUS THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4082552-B1 | LIQUIDS RICH IN NOBLE GAS AND METHODS OF THEIR PREPARATION AND USE | UNIV TEXAS (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12527326-B1 | Indoxacarb suspension concentrate formulations | CONTROL SOLUTIONS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-6090414-A | MIXTURE OF ANTIOXIDANT, SELENIUM AND SULFUR PEPTIDE | LIFE SCIENCE LABS, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-4208321-A | FILMS, FIBERS, SHEETS | PENNWALT CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-4208322-A | Polyester-polyamide resins flame retarded by poly(metal phosphinate)s | PENNWALT CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-4180495-A | Polyester resins flame retarded by poly(metal phosphinate)s | PENNWALT CORPORATION (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144834-A1 | ANTIMICROBIAL FEED ADDITIVE | ELOVL6, CROCC, ELOC | LMNA 2049/4885MAPK1 3819/4885SRC 3303/4885 |
| US-12629319-B2 | Injection apparatus and method of use | IL6, TNF, IL2 | LMNA 2041/4885MAPK1 724/4885SRC 491/4885 |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | LIPA, MMP8, MMP1 | LMNA 655/4885MAPK1 4286/4885SRC 2860/4885 |
| US-12527326-B1 | Indoxacarb suspension concentrate formulations | SCN2B, CACNG3, CACNA1G | LMNA 241/4885MAPK1 3378/4885SRC 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.